DEVELOPING THERAPIES FOR BRAIN METASTASES
MD Anderson and Taiho Pharmaceutical announced a three-year strategic
collaboration to accelerate the development of treatments for
significant unmet medical needs in oncology, including patients with
brain metastases and those with cancers refractory to available
therapies.